STOCK TITAN

Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Eiger BioPharmaceuticals reported financial results for Q2 2023 and provided a business update. They are focusing on avexitide in metabolic diseases, particularly post-bariatric hypoglycemia (PBH) and other forms of hyperinsulinemic hypoglycemia (HH). They also plan to develop avexitide for congenital hyperinsulinism. The company achieved net revenue of $4.6 million in Q2 2023. They have reduced their workforce by 25% and expect their cash runway to extend into Q4 2024. David Apelian has been appointed as the CEO. The company had a cash position of $53.6 million as of June 30, 2023.
Positive
  • None.
Negative
  • None.
  • Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications
  • Active discussions underway with potential partners to advance late-stage virology programs
  • Reduction in workforce executed to align with focus on avexitide; extends cash runway into Q4 2024
  • David Apelian, MD, PhD, MBA, appointed CEO

PALO ALTO, Calif., Aug. 14, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today reported financial results for the second quarter 2023 and provided a business update.

"We reported in late June that we are deploying our resources toward recognizing the compelling potential of avexitide in metabolic diseases," said David Apelian, MD, PhD, MBA, CEO of Eiger. "Our initial focus is on post-bariatric hypoglycemia, or PBH, and other forms of hyperinsulinemic hypoglycemia (HH) arising after gastrointestinal surgeries where we see the highest revenue potential, have demonstrated proof-of-concept in Phase 2 clinical trials, and have FDA alignment on Phase 3 endpoints, sample size, and study design. In the future, we also intend to develop avexitide for congenital hyperinsulinism as a second indication."

Business Highlights

Avexitide for Post-Bariatric Hypoglycemia (PBH)

  • A large orphan disease with a growing population; caused by complications in bariatric surgery
  • Prevalence of approximately 180,000 in the US and approximately half that in the EU
  • Avexitide is the only drug in development for PBH with Breakthrough Therapy designation
  • FDA alignment on pivotal Phase 3 study endpoints, sample size, and design

Avexitide for Congenital Hyperinsulinism (HI)

  • An ultra-rare, life-threatening, pediatric disorder of persistent hypoglycemia that results in irreversible brain damage in up to 50% of children
  • Breakthrough Therapy designation from FDA
  • Rare Pediatric Disease designation

Zokinvy® (lonafarnib) for Progeria and Processing-Deficient Progeroid Laminopathies

  • Achieved net revenue of $4.6 million in Q2 2023

Corporate

  • 25% reduction in workforce, a reduction in out-of-pocket spending related to the Company's hepatitis delta (HDV) development program and the Company's existing term loan are expected to extend the Company's cash runway into the fourth quarter of 2024
  • David Apelian, MD, PhD, MBA, appointed CEO

Cash Position

  • $53.6 million in cash position as of June 30, 2023

Second Quarter 2023 Financial Results

Total revenue was $4.6 million for the second quarter of 2023, as compared to $4.1 million for the same period in 2022. The increase was primarily driven by  the product sales in Germany compared to no such sales for the same period in 2022. The increase was partially offset by a decrease of certain upfront payments received under the terms of the Marketing and Distribution Agreement (MDA) with AnGes, Inc., which was executed in May 2022, relating to obtaining regulatory approval for and commercialization of Zokinvy in Japan.

Cost of sales decreased by $0.5 million in the second quarter 2023 compared to the same period in 2022. The decrease was primarily due to a reversal of an inventory accrual related to a nonconforming batch of product. During the second quarter 2023, the Company was notified by the vendor that it was no longer obligated to pay for that nonconforming batch of product.

Research and development expenses were $19.4 million for the second quarter of 2023, as compared to $17.0 million for the same period in 2022. The increase was primarily due to an increase in clinical and contract manufacturing expenditures and an increase in compensation and personnel related expense. The increase was partially offset by a decrease in outside services across programs, including consulting and advisory services due to a decline in spending on peginterferon lambda programs.

Selling, general and administrative expenses were $5.5 million for the second quarter of 2023, as compared to $7.0 million for the same period in 2022. The decrease was primarily due to a decrease in compensation and personnel related expense, including stock-based compensation, and a decrease in outside services, including consulting, advisory and accounting services.

Total operating expenses include non-cash expenses of $0.9 million for the second quarter of 2023, as compared to $4.1 million for the same period in 2022. The decrease was primarily due to a change in amortization of premiums and discounts on debt securities due to current market and economic conditions, a decrease in loss on early extinguishment of Oxford loan paid off in June 2022 and a decrease in stock based compensation expenses.

The Company reported a net loss of $20.7 million, or $0.47 per share basis for the second quarter of 2023. This compares to a net loss of $21.9 million, or $0.51 per share basis for the same period in 2022.

Cash, cash equivalents, and short-term debt securities as of June 30, 2023 totaled $53.6 million, as compared to $98.9 million as of December 31, 2022.

As of June 30, 2023, the Company had 44,296,417 common shares outstanding.

About Eiger

Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases. Eiger's lead product candidate, avexitide, is a well characterized, first-in-class GLP-1 antagonist being developed for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). Avexitide is the only drug in development for PBH with Breakthrough Therapy designation from the FDA.

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts, including statements regarding our future financial condition, timing for and outcomes of clinical results, prospective products, preclinical and clinical pipelines, regulatory objectives, business strategy and plans and objectives for future operations, are forward-looking statements. Forward-looking statements are our current statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the timing of our ongoing and planned clinical development; our capability to provide sufficient quantities of any of our products or product candidates for studies or to meet anticipated full-scale commercial demands; our ability to identify, pursue and enter into partnering opportunities for our virology assets; the sufficiency of our cash, cash equivalents and investments to fund our operations into the fourth quarter of 2024, including the scope and impact of any savings from our workforce reduction and cash conservation efforts; the revenue potential of avexitide in post-bariatric hypoglycemia and congenital hyperinsulinism; our ability to finance, independently or through collaborations, the continued advancement of our development pipeline; and the potential for success of any of our products or product candidates. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Eiger makes, including additional applicable risks and uncertainties described in the "Risk Factors" section in Eiger's Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 and Eiger's subsequent filings with the SEC. The forward-looking statements contained in this press release are based on information currently available to Eiger and speak only as of the date on which they are made. Eiger does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.

Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com   

Media:
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

 

Eiger BioPharmaceuticals Inc.
Condensed Consolidated Balance Sheets
(in thousands)



June 30, 
2023


December 31,
2022(1)


(Unaudited)



ASSETS




Cash and cash equivalents

$           22,983


$           25,798

Short-term debt securities

30,626


73,150

Accounts receivable

3,715


1,749

Inventories

1,098


2,853

Prepaid expenses and other current assets

12,062


13,985

Total current assets

70,484


117,535

Property and equipment, net

755


696

Operating lease right-of-use assets

329


561

Other assets

790


1,347

Total assets

$           72,358


$         120,139

LIABILITIES AND STOCKHOLDERS' EQUITY




Current liabilities

16,713


$           25,121

Other liabilities

40,350


39,708

Stockholders' equity

15,295


55,310

Total liabilities and stockholders' equity

$           72,358


$         120,139



(1)

Derived from the audited financial statements, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022.

 

Eiger BioPharmaceuticals Inc.
Condensed Consolidated Statements of Operations Financial Data
(in thousands, except per share and share amounts)

 



Three Months Ended
June 30,
(unaudited)


Six Months Ended
June 30,
(unaudited)


2023


2022


2023


2022

Product revenue, net

$              4,393


$              3,341


$              8,511


$              6,014

Other revenue

250


750


250


750

Total revenue

4,643


4,091


8,761


6,764

Costs and operating expenses:








Cost of sales

(310)


151


(192)


261

Research and development(1)

19,401


16,993


36,149


34,563

Selling, general and administrative(1)

5,533


7,027


15,048


13,840

Total operating expenses

24,624


24,171


51,005


48,664

Loss from operations

(19,981)


(20,080)


(42,244)


(41,900)

Interest expense

(1,343)


(934)


(2,628)


(1,820)

Interest income

660


221


1,371


266

Other income (expense), net

(29)


(1,074)


26


(1,047)

Income (loss) before provision for taxes

(20,693)


(21,867)


(43,475)


(44,501)

Provision for income taxes

2


17


4


26

Net loss

$          (20,695)


$          (21,884)


$          (43,479)


$          (44,527)

Net income (loss) per common share:








Basic and diluted

$              (0.47)


$              (0.51)


$              (0.98)


$              (1.14)

Weighted-average common shares outstanding:








Basic and diluted

44,296,417


43,059,809


44,221,442


39,178,043



(1)

Includes stock-based compensation expense of:

 


Three Months Ended
June 30,


Six Months Ended
June 30,


2023


2022


2023


2022

Research and development

$                 517


$                 820


$              1,351


$              1,445

General and administrative

228


1,388


1,936


2,810

Total stock-based compensation expense

$                 745


$              2,208


$              3,287


$              4,255

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-reports-second-quarter-2023-financial-results-and-provides-business-update-301900008.html

SOURCE Eiger BioPharmaceuticals, Inc.

FAQ

What is the focus of Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals is focusing on avexitide in metabolic diseases, particularly post-bariatric hypoglycemia (PBH) and other forms of hyperinsulinemic hypoglycemia (HH).

What are the key highlights of avexitide for PBH?

Avexitide is the only drug in development for PBH with Breakthrough Therapy designation. It has FDA alignment on pivotal Phase 3 study endpoints, sample size, and design.

What is avexitide being developed for besides PBH?

Avexitide is also being developed for congenital hyperinsulinism.

What is the cash position of Eiger BioPharmaceuticals?

As of June 30, 2023, Eiger BioPharmaceuticals had a cash position of $53.6 million.

Who has been appointed as the CEO of Eiger BioPharmaceuticals?

David Apelian, MD, PhD, MBA, has been appointed as the CEO of Eiger BioPharmaceuticals.

What is the workforce reduction of Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals has reduced its workforce by 25%.

What is the expected cash runway of Eiger BioPharmaceuticals?

The reduction in workforce and other measures are expected to extend the company's cash runway into Q4 2024.

Eiger BioPharmaceuticals, Inc.

NASDAQ:EIGR

EIGR Rankings

EIGR Latest News

EIGR Stock Data

2.55M
1.27M
11.8%
43.86%
2.27%
Biotechnology
Healthcare
Link
United States
Palo Alto